Pharmaceuticals · CONCORDB
Pharma - API & CRAMS
from 1,413 today
Concord Biotech reported a broadly in-line 1QFY27 performance driven by API growth, while injectables and Stellon Biotech are expected to drive the next leg of growth. We maintain our BUY rating with a revised target price of INR 1,700 based on 32x 1HFY29E EPS.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
